Arrowhead Pharmaceuticals Inc (ARWR)

Total asset turnover

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Revenue (ttm)	US$ in thousands	166,263	225,258	245,998	267,743	278,338	243,231	249,939	263,418	144,424	138,288	107,638	89,123	79,841	87,993	123,653	138,974	163,593	168,796	136,758	94,788
Total assets	US$ in thousands	626,286	765,552	795,856	891,308	891,489	691,939	751,782	703,575	638,539	710,148	734,927	756,795	499,251	522,504	555,728	561,076	587,602	349,845	336,828	333,940
Total asset turnover		0.27	0.29	0.31	0.30	0.31	0.35	0.33	0.37	0.23	0.19	0.15	0.12	0.16	0.17	0.22	0.25	0.28	0.48	0.41	0.28

December 31, 2023 calculation

Total asset turnover = Revenue (ttm) ÷ Total assets
= $166,263K ÷ $626,286K
= 0.27

The total asset turnover ratio measures a company's ability to generate revenue from its total assets. It indicates how efficiently the company is using its assets to generate sales.

Arrowhead Pharmaceuticals Inc.'s total asset turnover ratio has shown some fluctuations over the past eight quarters, ranging from 0.29 to 0.37. A higher ratio generally signifies better asset utilization efficiency.

In the most recent quarter, Q1 2024, the total asset turnover ratio was 0.29, indicating that the company generated $0.29 in sales for every $1 of assets. This was a decrease compared to the previous quarter, Q4 2023, where the ratio was 0.31.

Overall, Arrowhead Pharmaceuticals Inc. has experienced some variability in its total asset turnover ratio in recent quarters. It may be valuable for stakeholders to further evaluate the company's asset management strategies to ensure optimal utilization of assets for revenue generation.